Marginal Zone Lymphoma — Trials

Marginal Zone Lymphoma — Trials · CancerIndex

Clinical trials

Registered studies

407 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 111
Recruiting: 62
Ph III recruiting: 2
Growth YoY: —
Industry share: 22%
Top sponsor: City of Hope Medical Center
Termination share: 38.9%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (79)

clinicaltrialsPublishedShowing 1–7 of 7 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT04665115	Ibrutinib for the Treatment of Patients With B-Cell Malignancies Who Are Infected With Coronavirus Disease 2019 (COVID-19)	withdrawn	Phase 2	0	Academic and Community Cancer Research UnitedOTHER	1	Aug 3, 2022	clinicaltrials
NCT01460602	Velcade, Nipent, Rituxan (VNR) in Subjects With Relapsed Follicular, Marginal Zone, and Mantle Cell Lymphoma	withdrawn	Phase 1 / Phase 2	0	Louisiana State University Health Sciences Center ShreveportOTHER	1